Hereditary Angioedema (HAE) Therapeutics Market– By Treatment Type (C-1 Esterase Inhibitor, Kallikrein Inhibitor), Route of Administration (Oral, Parenteral), Age Group (Pediatric, Adult), Distribution Channel (Hospital Pharmacies, Online Pharmacies) – Global Forecast, 2024­2032

Hereditary Angioedema Therapeutics Market Size

Hereditary Angioedema Therapeutics Market size was valued at USD 4.1 billion in 2023 growing at a CAGR of 9.2% between 2024 and 2032. The key factors driving the growth of the market include rising awareness of hereditary angioedema (HAE) and advancements in diagnostic technology, such as improved genetic testing, leading to more diagnoses and increasing the number of patients requiring effective treatment options.
 

For instance, according to the Rare Disease Advisor Report, HAE episodes result in 15,000–30,000 emergency department visits in the U.S. each year. A survey of U.S. physicians revealed that the average time to diagnose HAE can range from 0–6 months to over 10 years, with fewer than 38% of patients receiving an accurate diagnosis within 1–3 years after symptoms appear. Enhanced awareness of HAE among healthcare professionals and patients, coupled with advancements in targeted therapies, such as the development of new complement inhibitors and bradykinin B2 receptor antagonists, is anticipated to foster market growth.
 

Hereditary angioedema (HAE) is an autosomal dominant disease caused by either a lack of C1-inhibitor protein or dysfunctional C1-inhibitor protein. The most feared complication of HAE is upper airway swelling, which can lead to asphyxiation. HAE therapeutics refer to medical treatments and interventions specifically designed to manage and alleviate the symptoms of the disease.
 

Hereditary Angioedema Therapeutics Market Trends

The ongoing innovation in the development of targeted therapies, such as new complement inhibitors and bradykinin B2 receptor antagonists, is driving market growth. These therapies offer better efficacy and safety compared to traditional treatments, making them attractive to both patients and healthcare providers. For instance, in May 2024, Ionis Pharmaceuticals, Inc. announced positive results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with hereditary angioedema (HAE), demonstrating a significant and sustained reduction in mean monthly HAE attack rates, with continued attack rate improvement of over 90% after one year of treatment for both monthly and every two-month dosing. Thus, the development and approval of new drugs are expanding the therapeutic options available for HAE, which is expected to contribute to market growth.
 

Hereditary Angioedema Therapeutics Market Analysis

Based on the treatment type, the market is classified into C1 esterase inhibitors, bradykinin B2 receptor antagonist, kallikrein inhibitor, and other treatment types. The C1 esterase inhibitors segment dominated the market with revenue of USD 1.8 billion in 2023.
 

• Increased awareness and understanding of Hereditary Angioedema (HAE) among healthcare professionals and the public have led to earlier diagnoses and treatments. This has boosted the demand for C1 esterase inhibitors, the primary treatment for acute HAE attacks, thereby contributing to the market's growth.
   
• Moreover, C1 esterase inhibitors are recognized for their safety and effectiveness as targeted therapies. The preference for these specific treatments over broader options is driving their increased demand, which boosts market growth.
   
• In addition, the growing use of C1 esterase inhibitors for long-term prevention in HAE patients has significantly boosted this segment. The shift from on-demand treatment to preventive care is a major factor in this trend, further driving market growth.
   

Based on the route of administration, the hereditary angioedema therapeutics market is segmented into oral and parenteral. The parenteral segment dominated the market with market share of 68.5% in 2023.
 

• Innovations in parenteral delivery systems, such as autoinjectors and needle-free devices, have made self-administration of HAE therapies easier and less painful. These advancements have increased patient compliance and made parenteral therapies more appealing, driving market growth.
   
• Additionally, new parenteral therapies, such as monoclonal antibodies and plasma-derived C1 esterase inhibitors, have expanded treatment options for HAE. These therapies, which require parenteral administration, have driven the segment's growth due to their improved efficacy and targeted action, further fuelling the market growth for parenteral formulations.
   

Based on the age group, the global hereditary angioedema therapeutics market is segmented into pediatric, adult, and geriatric. The adult segment dominated the market and is expected to reach USD 5.1 billion by 2032.

• With advancements in diagnostic techniques and greater awareness of HAE among healthcare providers, more adults are being accurately diagnosed with the condition. This has led to a growing demand for therapies specifically tailored to adult patients.
   
• Additionally, adult patients are often more proactive in seeking treatment due to a better understanding of their condition. The growth of patient advocacy groups and educational campaigns targeting adults has also contributed to increased demand for HAE therapies in this segment.
   

Based on distribution channel, the hereditary angioedema therapeutics market is classified into hospital pharmacies, drug store & retail pharmacies, and online pharmacies. The hospital pharmacies segment is expected to exhibit 9.5% CAGR between 2024-2032.
 

• Hospital pharmacies specialize in managing and dispensing HAE therapies, such as C1 esterase inhibitors and bradykinin receptor antagonists. These treatments require specific storage, handling, and administration, which hospital pharmacies are well-equipped to provide. As a result, patients and healthcare providers prefer hospital pharmacies for HAE medications.
   
• Moreover, hospital pharmacies are essential to the healthcare system, especially in specialized institutions treating complex conditions like HAE. Advanced diagnostic tools, such as genetic testing for HAE, are available in hospitals to ensure timely and accurate diagnoses. This availability of appropriate therapeutic products in hospital pharmacies contributes to market growth.
   

In 2023, North America secured a substantial market share of 46.8% in the global hereditary angioedema therapeutics market and is expected to dominate throughout the forecast period.
 

• North America's strong R&D infrastructure, especially in the U.S., has enabled the rapid development and approval of new HAE therapies. The presence of leading pharmaceutical companies, academic institutions, and research organizations in the region has driven innovation and the introduction of advanced treatments to the market.
   
• Moreover, the expansion of specialized clinics and treatment centers for rare diseases like HAE in North America has improved patient access to care. These centers offer comprehensive services, including the latest therapies, which support market growth by ensuring patients receive timely and effective treatment.
   

Germany is set to experience the highest growth rate in the European market.
 

• Germany's robust healthcare system ensures that patients can access specialized treatments for rare diseases like HAE. Advanced facilities and expert healthcare professionals support the adoption of innovative therapies, which promotes market growth.
   
• Furthermore, the presence of many leading pharmaceutical companies and research institutions in Germany, focused on developing and commercializing hereditary angioedema (HAE) therapies, drives innovation and ensures that access to advanced treatments expands, thereby boosting market growth.
   

The Asia Pacific hereditary angioedema therapeutics market is expected to grow with a significant CAGR of 9.7% during the forecast period.
 

• The adoption of genetic testing in Asia-Pacific has seen a notable rise, which is crucial for the diagnosis of hereditary conditions like HAE. With improved genetic testing facilities and services, more patients are being accurately diagnosed, leading to a higher demand for targeted therapeutics.
   
• Moreover, the rise of local biopharmaceutical companies in countries like China and India has contributed to the market's growth. These companies are not only manufacturing but also developing new therapeutics that are more affordable, catering to the price-sensitive markets in the region, which further drives market growth.
   

Hereditary Angioedema Therapeutics Market Share

The market is characterized by intense competition among key players aiming to expand their market presence. Leading companies focus on strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their market position. These efforts aim to enhance their product and service offerings, expand their geographic reach, and invest in advanced technologies. The market also witnesses the entry of new players, further intensifying the competitive landscape.
 

Hereditary Angioedema Therapeutics Market Companies

The company profile section includes both companies that have commercial drug available in the market as well as those that are onto clinical phase development. Prominent players operating in the market are as mentioned below:

• Attune Pharmaceuticals
• BioCryst Pharmaceuticals, Inc.
• Biomarin
• CSL Behring LLC
• Intellia Therapeutics
• Ionis Pharmaceuticals
• KalVista Pharmaceuticals, Inc.
• Pharming Healthcare, Inc.
• Pharvaris
• Takeda Pharmaceutical Company Ltd
   

Hereditary Angioedema Therapeutics Industry News:

• In December 2023, Ionis Pharmaceuticals, Inc. announced that it has entered into a license agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) under which Otsuka obtains exclusive rights in Europe to commercialize donidalorsen, an investigational prophylactic treatment for hereditary angioedema (HAE). This strategic agreement helped both the companies expand its product offerings for HAE.
   
• In July 2021, Orchard Therapeutics and Pharming Group N.V. announced a strategic collaboration to research, develop, manufacture, and commercialize OTL-105, a newly disclosed investigational ex vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE). This collaboration aimed to broaden the treatment availability, and helped the company expand its product offerings.
   

The hereditary angioedema therapeutics market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Treatment Type

• C1-esterase inhibitor
• Bradykinin B2 receptor antagonist
• Kallikrein inhibitor
• Other treatment types

Market, By Route of Administration

• Oral
• Parenteral

Market, By Age Group

• Pediatric
• Adult
• Geriatric

Market, By Distribution Channel

• Hospital pharmacies
• Drug store & retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa